After a 31-year career at Swiss firm Roche Pharmaceuticals, including a six-year stint as CEO, American Daniel O’Day is moving on to head Gilead Sciences, Inc. taking the top leadership role there as chairman and CEO.
Meanwhile, Roche has tapped William Anderson, CEO at Roche-owned Genentech Inc., to take O’Day’s position at Roche’s helm. Read more about this shuffling of leadership among some of the biggest names in pharma, including reactions by analysts and investors, in this informative article from Scrip.
Meanwhile, Roche has tapped William Anderson, CEO at Roche-owned Genentech Inc., to take O’Day’s position at Roche’s helm. Read more about this shuffling of leadership among some of the biggest names in pharma, including reactions by analysts and investors, in this informative article from Scrip.
